Back to top
more

GoodRx (GDRX)

(Delayed Data from NSDQ)

$5.94 USD

5.94
848,435

+0.07 (1.19%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $5.94 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (154 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Organon (OGN) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Organon (OGN) delivered earnings and revenue surprises of 2.35% and 1.37%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Life Time Group Holdings, Inc. (LTH) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Life Time Group Holdings (LTH) delivered earnings and revenue surprises of 23.81% and 1.69%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

ELV vs. GDRX: Which Stock Is the Better Value Option?

by Zacks Equity Research

ELV vs. GDRX: Which Stock Is the Better Value Option?

GoodRx (GDRX) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for GoodRx (GDRX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

GoodRx Holdings, Inc. (GDRX) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

GoodRx (GDRX) delivered earnings and revenue surprises of -11.11% and 0.03%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

LifeMD, Inc. (LFMD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

LifeMD (LFMD) delivered earnings and revenue surprises of -46.15% and 4.53%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Unveiling GoodRx (GDRX) Q2 Outlook: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for GoodRx (GDRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.

Teladoc (TDOC) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Teladoc (TDOC) delivered earnings and revenue surprises of 22.22% and 1.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

ICLR vs. GDRX: Which Stock Is the Better Value Option?

by Zacks Equity Research

ICLR vs. GDRX: Which Stock Is the Better Value Option?

GoodRx (GDRX) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

GoodRx Holdings, Inc. (GDRX) Misses Q1 Earnings Estimates

by Zacks Equity Research

GoodRx (GDRX) delivered earnings and revenue surprises of -11.11% and 0.86%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Premier, Inc. (PINC) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Premier (PINC) delivered earnings and revenue surprises of 17.02% and 9.48%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Countdown to GoodRx (GDRX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for GoodRx (GDRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Is GoodRx (GDRX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how GoodRx Holdings, Inc. (GDRX) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.

ELV vs. GDRX: Which Stock Is the Better Value Option?

by Zacks Equity Research

ELV vs. GDRX: Which Stock Is the Better Value Option?

ELV or GDRX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ELV vs. GDRX: Which Stock Is the Better Value Option?

Wall Street Analysts Predict a 29.1% Upside in GoodRx Holdings, Inc. (GDRX): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 29.1% upside potential for GoodRx Holdings, Inc. (GDRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Encompass Health (EHC), Piedmont to Build Loganville Facility

by Zacks Equity Research

Encompass Health (EHC) partners with Piedmont to construct a 40-bed inpatient rehabilitation hospital in Georgia to better serve the rehabilitative care needs of the state and solidify its footprint.

ELV or GDRX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ELV vs. GDRX: Which Stock Is the Better Value Option?

Can GoodRx Holdings, Inc. (GDRX) Run Higher on Rising Earnings Estimates?

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

GoodRx Holdings, Inc. (GDRX) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does GoodRx Holdings, Inc. (GDRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

GoodRx Holdings, Inc. (GDRX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for GoodRx Holdings, Inc. (GDRX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

GoodRx Holdings, Inc. (GDRX) Matches Q4 Earnings Estimates

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 0% and 0.54%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Agiliti (AGTI) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Agiliti (AGTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What to Look for in Crescent Point's (CPG) Q4 Earnings?

by Zacks Equity Research

Lower price realizations and an upward cost trajectory are likely to have dented Crescent Point Energy's (CPG) fourth-quarter results.